• Consensus Rating: Buy
  • Consensus Price Target: GBX 2,700
  • Forecasted Upside: 13.45%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
GBX 2,380
▲ +30 (1.28%)

This chart shows the closing price for CRW by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Craneware Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CRW and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CRW

Analyst Price Target is GBX 2,700
▲ +13.45% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Craneware in the last 3 months. The average price target is GBX 2,700, with a high forecast of GBX 2,700 and a low forecast of GBX 2,700. The average price target represents a 13.45% upside from the last price of GBX 2,380.

This chart shows the closing price for CRW for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 polled investment analysts is to buy stock in Craneware. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/3/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/4/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/2/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/31/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/29/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/28/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/27/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/27/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
7/18/2024Berenberg BankBoost TargetBuyGBX 2,600 ➝ GBX 2,700
7/2/2024Berenberg BankReiterated RatingBuyGBX 2,600
3/4/2024Berenberg BankBoost TargetBuyGBX 2,300 ➝ GBX 2,600
9/5/2023Berenberg BankReiterated RatingBuyGBX 2,300
3/6/2023Shore CapitalReiterated RatingBuyGBX 2,300
9/20/2022Berenberg BankBoost TargetBuyGBX 2,320 ➝ GBX 2,600
7/26/2022Berenberg BankLower TargetBuyGBX 2,725 ➝ GBX 2,320
3/22/2022Berenberg BankReiterated RatingBuyGBX 2,725
3/14/2022Berenberg BankLower TargetBuyGBX 3,100 ➝ GBX 2,725
2/1/2022Berenberg BankReiterated RatingBuyGBX 3,100
12/1/2021Berenberg BankReiterated RatingBuyGBX 3,100
11/4/2021Berenberg BankBoost TargetBuyGBX 2,750 ➝ GBX 3,100
6/11/2021Berenberg BankReiterated RatingBuyGBX 2,420
3/1/2021Berenberg BankBoost TargetBuyGBX 2,200 ➝ GBX 2,420
7/9/2020Berenberg BankReiterated RatingBuy
7/8/2020Peel HuntReiterated RatingBuy
6/5/2020Berenberg BankReiterated RatingBuyGBX 2,200
4/16/2020Peel HuntReiterated RatingBuy
3/31/2020Berenberg BankLower TargetBuyGBX 2,500 ➝ GBX 2,200
3/10/2020Peel HuntReiterated RatingBuy
3/3/2020Peel HuntReiterated RatingBuy
2/24/2020Peel HuntReiterated RatingBuy
1/27/2020Panmure GordonReiterated RatingHold
1/23/2020Peel HuntReiterated RatingBuyGBX 3,000
1/23/2020Berenberg BankReiterated RatingBuyGBX 2,500
1/23/2020Peel HuntReiterated RatingBuyGBX 3,000
12/18/2019Peel HuntReiterated RatingBuy
11/12/2019Peel HuntReiterated RatingBuyGBX 3,000
11/12/2019Peel HuntReiterated RatingBuyGBX 3,000
10/8/2019Peel HuntReiterated RatingBuy
9/9/2019Peel HuntReiterated RatingBuy
9/3/2019Berenberg BankReiterated RatingBuyGBX 2,500
9/2/2019Peel HuntReiterated RatingBuy
8/5/2019Peel HuntReiterated RatingBuy
(Data available from 7/27/2019 forward)

News Sentiment Rating

0.53 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/30/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/29/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/28/2024
  • 0 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
3/29/2024
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
4/28/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/28/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/27/2024
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/27/2024

Current Sentiment

  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.
Craneware logo
Craneware plc, together with its subsidiaries, develops, licenses, and supports computer software for the healthcare industry in the United States. The company provides solutions, such as Trisus pricing transparency software; Trisus Pricing Analyzer, a solution that simplifies and automates the price modeling process; Trisus Chargemaster, an automated chargemaster management solution; InSight Medical Necessity, a solution that offers medical necessity for the United States payors; Trisus Claims Informatics, a retrospective charge capture analytical application that identifies areas of risk for its team to investigate; Trisus Supply, a solution that improves supplies reimbursement; and InSight Audit, an audit management solution for government and commercial payors. It also offers Trisus Decision Support; Trisus Labor Productivity; Trisus Medication Analytic solutions; and Trisus supplies assistant solutions. In addition, the company provides Sentinel, a drug tracking solution; Sentrex, a SaaS-based solution that helps covered entities expand medication access; Referral Verification System; and Central Pharmacy Distribution, a centralized purchasing application. Further, it offers appeal, professional, and pharmacy professional services. Craneware plc was incorporated in 1999 and is headquartered in Edinburgh, the United Kingdom.
Read More

Today's Range

Now: GBX 2,380
Low: 2,350
High: 2,400

50 Day Range

MA: GBX 2,337.15
Low: 2,180
High: 2,470

52 Week Range

Now: GBX 2,380
Low: 1,290
High: 2,509.20

Volume

5,362 shs

Average Volume

80,347 shs

Market Capitalization

£840.62 million

P/E Ratio

11,333.33

Dividend Yield

1.30%

Beta

0.14

Frequently Asked Questions

What sell-side analysts currently cover shares of Craneware?

The following Wall Street analysts have issued reports on Craneware in the last year: Berenberg Bank.
View the latest analyst ratings for CRW.

What is the current price target for Craneware?

1 Wall Street analysts have set twelve-month price targets for Craneware in the last year. Their average twelve-month price target is GBX 2,700, suggesting a possible upside of 13.4%. Berenberg Bank has the highest price target set, predicting CRW will reach GBX 2,700 in the next twelve months. Berenberg Bank has the lowest price target set, forecasting a price of GBX 2,700 for Craneware in the next year.
View the latest price targets for CRW.

What is the current consensus analyst rating for Craneware?

Craneware currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CRW will outperform the market and that investors should add to their positions of Craneware.
View the latest ratings for CRW.

What other companies compete with Craneware?

Other companies that are similar to Craneware include EMIS Group, Instem, Kooth, Renalytix and Cambridge Cognition. Learn More about companies similar to Craneware.

How do I contact Craneware's investor relations team?

Craneware's physical mailing address is 1 Tanfield, EDINBURGH, EH3 5DA, United Kingdom. The company's listed phone number is +44-131-5503100. The official website for Craneware is public.craneware.com. Learn More about contacing Craneware investor relations.